Skip to main content

Advertisement

SpringerLink
Log in

Full macular translocation (FMT) versus photodynamic therapy (PDT) with verteporfin in the treatment of neovascular age-related macular degeneration: 2-year results of a prospective, controlled, randomised pilot trial (FMT-PDT)

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Background

To report the outcome of best-corrected visual acuity (BCVA), near visual acuity (NVA), contrast sensitivity (CS) and vision-related quality of life (VRQOL) in patients 2 years after undergoing photodynamic therapy (PDT) or full macular translocation (FMT) for the treatment of neovascular age-related macular degeneration (AMD).

Methods

Fifty patients with predominantly classic subfoveal choroidal neovascularisation (CNV) secondary to AMD were randomized to PDT or FMT. BCVA was determined according a standardized protocol with ETDRS charts. NVA were calculated after testing with SNAB (Swiss National Association of and for the Blind) visual acuity cards. CS was measured with Pelli-Robson charts. The 39-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25 plus supplement) was performed. Primary end points were the changes of BCVA, NVA, CS and VRQOL at 24-month examination.

Results

A stabilisation of BCVA (+0.3 letters) was found in the FMT group, whereas a decrease of more than 12 letters (-12.6 letters) was found in the PDT group (p = 0.052). Mean NVA improved by 7.0 letters in the FMT group and was superior to the PDT group (−9.6 letters, p = 0.036), while mean CS showed a time-dependent decrease in both treatment groups (FMT: −3.3 letters, PDT: −3.8 letters, p = 0.726). Considering the results of the VRQOL scores, the improvement of the subscales scores for general vision (p = 0.015), mental health (p = 0.028) and near activity (p = 0.020) were significantly higher in the FMT group.

Conclusions

FMT can stabilise BCVA and improve NVA over a period of 2 years in patients with subfoveal classic CNV secondary to neovascular AMD, whereas a decrease of BCVA and NVA was found in the PDT group. CS did not differ between FMT and PDT. A significant increase of VRQOL scores was only found in the FMT group and not in the PDT group. FMT seems to be a therapeutic approach that can increase visual function resulting in an improvement of patient’s VRQOL, but exhibits a higher number of severe complications compared to PDT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Klein R, Klein BE, Linton KL (1992) Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 99:933–943

    PubMed  CAS  Google Scholar 

  2. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, ANCHOR Study Group (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355(14):1432–1444. doi:10.1056/NEJMoa062655

    Article  PubMed  CAS  Google Scholar 

  3. Pieramici DJ, Avery RL (2006) Ranibizumab: treatment in patients with neovascular age-related macular degeneration. Expert Opin Biol Ther 6(11):1237–1245. doi:10.1517/14712598.6.11.1237

    Article  PubMed  CAS  Google Scholar 

  4. Gelisken F, Voelker M, Schwabe R, Besch D, Aisenbrey S, Szurman P, Grisanti S, Herzau V, Bartz-Schmidt KU (2007) Full macular translocation versus photodynamic therapy with verteporfin in the treatment of neovascular age-related macular degeneration: 1-year results of a prospective, controlled, randomised pilot trial (FMT-PDT). Graefes Arch Clin Exp Ophthalmol 245(8):1085–1095. doi:10.1007/s00417-006-0524-y

    Article  PubMed  CAS  Google Scholar 

  5. Lüke M, Ziemssen F, Bartz-Schmidt KU, Gelisken F (2007) Quality of life in a prospective, randomised pilot-trial of photodynamic therapy versus full macular translocation in treatment of neovascular age-related macular degeneration—a report of 1 year results. Graefes Arch Clin Exp Ophthalmol 245(12):1831–1836. doi:10.1007/s00417-007-0558-9

    Article  PubMed  Google Scholar 

  6. Ziemssen F, Lüke M, Bartz-Schmidt KU, Gelisken F (2008) Time-dependent effects on contrast sensitivity, near and distance acuity: difference in functional parameters? (Prospective, randomized pilot trial of photodynamic therapy versus full macular translocation). Graefes Arch Clin Exp Ophthalmol 246(5):653–659. doi:10.1007/s00417-007-0726-y

    Article  PubMed  Google Scholar 

  7. Colenbrander A, Fletcher DC (1990) Visual acuity measurements in low vision patients. J Vis Rehabil 4:1–9

    Google Scholar 

  8. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD, National Eye Visual Function Questionnaire Field Test Investigators (2001) Development of the 25-item National eye institute visual function questionnaire. Arch Ophthalmol 119:1050–1058

    PubMed  CAS  Google Scholar 

  9. Stelmack JA, Stelmack TR, Massof RW (2002) Measuring low-vision rehabilitation outcomes with the NEI VFQ-25. Invest Ophthalmol Vis Sci 43:2859–2868

    PubMed  Google Scholar 

  10. Clemons TE, Chew EY, Bressler SB, McBee W, for the AREDS Research Group (2003) National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS). Arch Ophthalmol 121:211–217

    PubMed  Google Scholar 

  11. Mangione CM, Berry S, Spritzer K (1998) Identifying the content area for the 51-item National Eye Institute Visual Function Questionaire: results from focus groups with visually impaired persons. Arch Ophthalmol 116:227–233

    PubMed  CAS  Google Scholar 

  12. Franke GH, Esser J, Voigtländer A, Mähner N (1998) Der National Eye Institute Visual Function Questionnaire (NEI-VFQ) — Erste Ergebnisse zur psychometrischen Überprüfung eines Verfahrens zur Erfassung der Lebensqualität bei Sehbeeinträchtigten. Z Mol Psychol 7:178–184

    Google Scholar 

  13. Mangione CM (2000) The NEI VFQ-25 Scoring Algorithm. http://catalog.nei.nih.gov/productcart/pc/viewPrd.asp?idcategory=50&idproduct=60#)

  14. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of two randomized clinical trials. TAP Report 1. Arch Ophthalmol 117:1329–1345

    Google Scholar 

  15. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year results of two randomized clinical trials. TAP Report 2. Arch Ophthalmol 119:198–207

    Google Scholar 

  16. Eckardt C, Eckardt U, Conrad H-G (1999) Macular rotation with or without counter-rotation of the globe of the patients with agerelated macular degeneration. Graefes Arch Clin Exp Ophthalmol 237:313–325. doi:10.1007/s004170050239

    Article  PubMed  CAS  Google Scholar 

  17. Aisenbrey S, Lafaut BA, Szurman P, Grisanti S, Luke C, Krott R, Thumann G, Fricke J, Neugebauer A, Hilgers RD, Esser P, Walter P, Bartz-Schmidt KU (2002) Macular translocation with 360 degrees retinotomy for exudative age-related macular degeneration. Arch Ophthalmol 120:451–459

    PubMed  Google Scholar 

  18. Abdel-Meguid A, Lappas A, Hartmann K, Auer F, Schrage N, Thumann G, Kirchhof B (2003) One year follow up of macular translocation with 360 degree retinotomy in patients with age related macular degeneration. Br J Ophthalmol 87:615–621. doi:10.1136/bjo.87.5.615

    Article  PubMed  CAS  Google Scholar 

  19. Mruthyunjaya P, Stinnett SS, Toth CA (2004) Change in visual function after macular translocation with 360° retinectomy for neovascular age-related macular degeneration. Ophthalmology 111:1715–1724. doi:10.1016/j.ophtha.2004.03.022

    Article  PubMed  Google Scholar 

  20. McClure ME, Hart PM, Jackson AJ, Stevenson MR, Chakravarthy (2000) Macular degeneration: do conventional measurements of impaired visual function equate with visual disability? Br J Ophthalmol 84:244–250. doi:10.1136/bjo.84.3.244

  21. Tejeria L, Harper RA, Artes PH, Dickinson CM (2007) Face recognition in age related macular degeneration: perceived disability, measured disability, and performance with a bioptic device. Br J Ophthalmol 86:1019–1026. doi:10.1136/bjo.86.9.1019

    Article  Google Scholar 

  22. Patel I, Turano KA, Broman AT, Bandeen-Roche K, Munoz B, West SK (2006) Measures of visual function and percentage of preferred walking speed in older adults. Invest Ophthalmol Vis Sci 47:65–71. doi:10.1167/iovs.05-0582

    Article  PubMed  Google Scholar 

  23. Lord SR, Clark RD, Webster IW (1991) Visual acuity and contrast sensitivity in relation to falls in an elderly population. Age Ageing 20:175–181. doi:10.1093/ageing/20.3.175

    Article  PubMed  CAS  Google Scholar 

  24. Lee HKM, Scudds RJ (2003) Comparison of balance in older people with and without visual impairment. Age Ageing 32:643–649. doi:10.1093/ageing/afg110

    Article  PubMed  Google Scholar 

  25. Cahill MT, Stinnett SS, Banks AD, Freedman SF, Toth CA (2005) Quality of Life after Macular Translocation with 360° Peripheral Retinectomy for Age-Related Macular Degeneration. Ophthalmology 112:144–151. doi:10.1016/j.ophtha.2004.06.035

    Article  PubMed  Google Scholar 

  26. Hewitt AW, Jeganathan SV, Kidd JE, Pesudovs K, Verma N (2006) Influence of photodynamic therapy for age related macular degeneration upon subjective vision related quality of life. Graefes Arch Clin Exp Ophthalmol 244(8):972–977. doi:10.1007/s00417-005-0218-x

    Article  PubMed  Google Scholar 

  27. Armbrecht AM, Aspinall PA, Dhillon B (2004) A prospective study of visual function and quality of life following PDT in patients with wet age related macular degeneration. Br J Ophthalmol 88:1270–1273. doi:10.1136/bjo.2003.038604

    Article  PubMed  CAS  Google Scholar 

  28. Cahill MT, Banks AD, Stinnett SS, Toth CA (2005) Vision-Related Quality of Life in Patients with Bilateral Severe Age-related Macular Degeneration. Ophthalmology 112(1):152–158. doi:10.1016/j.ophtha.2004.06.036

    Article  PubMed  Google Scholar 

  29. Casten RJ, Rovner BW, Tasman W (2004) Age-related macular degeneration and depression: a review of recent research. Curr Opin Ophthalmol 15(3):181–183. doi:10.1097/01.icu.0000120710.35941.3f

    Article  PubMed  Google Scholar 

  30. Brody BL, Gamst AC, Williams RA, Smith AR, Lau PW, Dolnak D, Rapaport MH, Kaplan RM, Brown SI (2001) Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology 108(10):1893–1900. doi:10.1016/S0161-6420(01)00754-0

    Article  PubMed  CAS  Google Scholar 

  31. Yang Y, ANCHOR study group (2007) Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3 mg and 0.5 mg with verteporfin photodynamic therapy for predominantly classic CNV lesions secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci 48:A4545

    Google Scholar 

  32. Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR (2007) MARINA Study Group. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 125(11):1460–1469

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgement

This study was supported in part by a grant (AKF project no. 46-0-0) from the University of Tuebingen.

Author information

Authors and Affiliations

  1. University Eye Hospital, University of Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany

    Matthias Lüke & Julia Beutel

  2. University Eye Hospital, Centre for Ophthalmology, Eberhard-Karls University of Tuebingen, Schleichstr. 12-16, 72076, Tuebingen, Germany

    Matthias Lüke, Focke Ziemssen, Michael Völker, Elke Altpeter, Julia Beutel, Dorothea Besch, Karl Ulrich Bartz-Schmidt & Faik Gelisken

Authors
  1. Matthias Lüke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Focke Ziemssen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Völker
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elke Altpeter
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Julia Beutel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dorothea Besch
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Karl Ulrich Bartz-Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Faik Gelisken
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthias Lüke.

Additional information

Matthias Lüke and Focke Ziemssen contributed to the manuscript equally.

The authors have no competing interests related to the manuscript.

The authors have no financial interests related to the manuscript.

The authors have no competing interests related to the manuscript.

All the authors had full access to all the data in the study. The authors had full control of the primary data. The authors agree to allow Graefe’s Archive of Clinical and Experimental Research to review their data if requested. This work was presented in part at the 106th Congress of the German Society of Ophthalmology.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lüke, M., Ziemssen, F., Völker, M. et al. Full macular translocation (FMT) versus photodynamic therapy (PDT) with verteporfin in the treatment of neovascular age-related macular degeneration: 2-year results of a prospective, controlled, randomised pilot trial (FMT-PDT). Graefes Arch Clin Exp Ophthalmol 247, 745–754 (2009). https://doi.org/10.1007/s00417-009-1050-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-009-1050-5

Keywords

Search

Navigation